Raseglurant
Raseglurant (INN) (code name ADX-10059) is a negative allosteric modulator of the mGlu5 receptor and derivative of MPEP which was under development by Addex Therapeutics for the treatment of migraine, gastroesophageal reflux disease, and dental anxiety. It reached phase II clinical trials for all of the aforementioned indications before being discontinued due to the observation of possible predictive signs of hepatotoxicity in patients with long-term use.
Wikipage redirect
primaryTopic
Raseglurant
Raseglurant (INN) (code name ADX-10059) is a negative allosteric modulator of the mGlu5 receptor and derivative of MPEP which was under development by Addex Therapeutics for the treatment of migraine, gastroesophageal reflux disease, and dental anxiety. It reached phase II clinical trials for all of the aforementioned indications before being discontinued due to the observation of possible predictive signs of hepatotoxicity in patients with long-term use.
has abstract
Raseglurant (INN) (code name A ...... n patients with long-term use.
@en
ATC prefix
CAS number
757950-09-7
IUPAC name
2-[(3-Fluorophenyl)ethynyl]-4,6-dimethyl-3-pyridinamine
@en
PubChem
thumbnail
Link from a Wikipage to an external page
Wikipage page ID
44,864,362
Wikipage revision ID
745,115,997
ChemSpiderID
molecular weight
2.40276e+2
smiles
StdInChIKey
MEDCLNYIYBERKO-UHFFFAOYSA-N
hypernym
comment
Raseglurant (INN) (code name A ...... n patients with long-term use.
@en
label
Raseglurant
@en